Genelux Corporation (GNLX)
| Market Cap | 114.72M -35.3% |
| Revenue (ttm) | 8,000 |
| Net Income | -35.60M |
| EPS | -0.86 |
| Shares Out | 44.81M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 154,649 |
| Open | 2.480 |
| Previous Close | 2.500 |
| Day's Range | 2.470 - 2.570 |
| 52-Week Range | 2.290 - 8.535 |
| Beta | 0.58 |
| Analysts | Strong Buy |
| Price Target | 18.83 (+635.55%) |
| Est. Earnings | Nov 4, 2026 |
About GNLX
Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec (olvimulogene nanivacirepvec), a proprietary modified strain of the vaccinia virus indicated for the treatment of ovarian cancer. It also offers CHOICE, a technology and discovery and development platform; and developed an extensive library of isolated and engineered oncolytic VACV immunotherapeutic product... [Read more]
Financial Performance
In 2025, Genelux's revenue was $8,000, a change of 0.00% compared to the previous year's $8,000. Losses were -$32.15 million, 7.62% more than in 2024.
Financial StatementsAnalyst Summary
According to 6 analysts, the average rating for GNLX stock is "Strong Buy." The 12-month stock price target is $18.83, which is an increase of 635.55% from the latest price.
News
Genelux assumed with a Buy at Lucid Capital
Lucid Capital analyst Dev Prasad assumed coverage of Genelux (GNLX) with a Buy rating and price target of $18, up from $10. The share setup is attractive into the Phase…
Genelux publishes case report from dose escalation portion of OLVI-VEC-202-SCLC
Genelux (GNLX) announced the publication of a case report from the ongoing Phase 1b dose escalation portion of its Phase 1b/2 OLVI-VEC-202-SCLC trial. The report was published in Frontiers in…
Genelux Announces Publication of a Deep and Durable Response in a Platinum-relapsed Small Cell Lung Cancer Patient Following Systemically Delivered Olvi-Vec-Primed Immunochemotherapy
-- A platinum-relapsed SCLC patient achieved 16.7 months progression-free survival following Olvi-Vec and platinum rechallenge, exceeding the PFS achieved following platinum-based first-line therapy -...
Genelux reports Q2 EPS (21c), consensus (20c)
“During the second quarter, the Company continued to make meaningful clinical and operational progress. We look forward to reporting the upcoming topline data of our Phase 3 OnPrime/GOG-3076 registrat...
Genelux expects cash to fund operations into Q1 of 2027
Cash, cash equivalents, marketable securities and restricted cash were $18.7M as of June 30, 2026. The Company expects that combined cash, cash equivalents, marketable securities and restricted cash w...
Genelux reports Q2 EPS (21c), consensus (20c)
“During the second quarter, the Company continued to make meaningful clinical and operational progress. We look forward to reporting the upcoming topline data of our Phase 3 OnPrime/GOG-3076 registrat...
Genelux Corporation Reports Second Quarter Financial Results and Provides Business Updates
-- Topline data from Phase 3 OnPrime/GOG-3076 ovarian cancer registrational trial of Olvi-Vec expected in 2H26 -- -- Olvi-Vec systemic development programs continue to advance, with additional dose-e...
Genelux Quarterly report: Q2 2026
Genelux has published its Q2 2026 quarterly earnings report on August 13, 2026.
Genelux Earnings release: Q2 2026
Genelux released its Q2 2026 earnings on August 13, 2026, summarizing the period's financial results.
Genelux Slides: Corporate presentation
Genelux has posted slides in relation to its latest quarterly earnings report, which was published on August 13, 2026.
Genelux Announces Publication of Translational Analysis Supporting Immune Activation and Chemotherapy Sensitization with Olvi‑Vec in Ovarian Cancer
- Findings provide mechanistic support for previously reported clinical outcomes of clinical reversal of platinum resistance/refractoriness from Phase 2 VIRO-15 trial -
Genelux Transcript: AGM 2026
The meeting covered the election of a director and auditor ratification, with both proposals approved. No shareholder questions were received, and final voting results will be filed with the SEC.
Genelux reports Q1 EPS (20c), consensus (19c)
“As we build on our momentum entering 2026, we remain focused on disciplined execution of our registrational program. The randomized Phase 3 OnPrime/GOG-3076 trial remains on track for topline data…
Genelux Corporation Reports First Quarter Financial Results and Provides Business Updates
-- Topline data from randomized Phase 3 OnPrime/GOG-3076 ovarian cancer registrational trial of Olvi-Vec expected in 2H26 -- -- Systemic lung cancer programs advancing with additional updates expected...
Genelux Quarterly report: Q1 2026
Genelux has published its Q1 2026 quarterly earnings report on May 7, 2026.
Genelux Earnings release: Q1 2026
Genelux released its Q1 2026 earnings on May 7, 2026, summarizing the period's financial results.
Genelux Slides: Corporate presentation
Genelux has posted slides in relation to its latest quarterly earnings report, which was published on May 7, 2026.
Genelux Proxy statement: Proxy filing
Genelux filed a proxy statement on April 29, 2026, providing details for shareholder voting and corporate governance matters.
Genelux Proxy statement: Proxy filing
Genelux filed a proxy statement on April 29, 2026, providing details for shareholder voting and corporate governance matters.
Genelux price target lowered to $20 from $23 at Benchmark
Benchmark lowered the firm’s price target on Genelux (GNLX) to $20 from $23 and keeps a Speculative Buy rating on the shares after adjusting the firm’s sum-of-the-parts analysis for the…
Genelux Corporation Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates
-- Topline data from Phase 3 OnPrime/GOG-3076 ovarian cancer registrational trial of Olvi-Vec expected in 2H26 -- -- Interim systemic lung cancer data with Olvi-Vec demonstrated partial responses in r...
Genelux Annual report: Q4 2025
Genelux has published its Q4 2025 annual report on March 19, 2026.
Genelux Earnings release: Q4 2025
Genelux released its Q4 2025 earnings on March 19, 2026, summarizing the period's financial results.
Genelux Transcript: Fireside chat
The discussion highlighted Olvi-Vec's potential as a backbone therapy in oncology, showing strong efficacy in platinum-resistant ovarian cancer and promising early results in lung cancer. The company is preparing for commercial launch, expanding indications, and expects pivotal data later this year.
Genelux Corporation Announces Upcoming Virtual Fireside Chat Hosted by Titan Partners
WESTLAKE VILLAGE, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Thomas Zindrick, President, CEO and ...